Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
Dispatch

Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India

Sriram Selvaraju, Muthusamy Santhosh Kumar, Jeromie Wesley Vivian Thangaraj, Tarun Bhatnagar, Velusamy Saravanakumar, Chethrapilly Purushothaman Girish Kumar, Krithikaa Sekar, Ezhilarasan Ilayaperumal, Ramasamy Sabarinathan, Murugesan Jagadeesan, Masanam Sriramulu Hemalatha, Manoj Vasant MurhekarComments to Author , and the Chennai COVID Sero-Surveillance Team
Author affiliations: Indian Council of Medical Research–National Institute for Research in Tuberculosis, Chennai, India (S. Selvaraju, K. Sekar, E. Ilayaperumal); ICMR–National Institute of Epidemiology, Chennai (M. Santhosh Kumar, J.W. Vivian Thangaraj, T. Bhatnagar, V. Saravanakumar, C.P. Girish Kumar, R. Sabarinathan, M.V. Murhekar); Greater Chennai Corporation, Chennai (M. Jagadeesan, M.S. Hemalatha)

Main Article

Table 2

Characteristics of persons with IgG against SARS-CoV-2, Chennai, India, July 2020*

Characteristics No. tested No. positive Unadjusted
seroprevalence,
% (95% CI) Weighted seroprevalence,
% (95% CI) p value Test performance-adjusted seroprevalence, % (95% CI)
Overall
 12,405
 2,673
 21.5 (20.8–22.3)
 18.7 (15.1–22.9)
 NA
 18.4 (14.8–22.6)
Sex
M 5,785 1,115 19.3 (18.3–20.3) 16.6 (13.2–20.6) <0.001 16.3 (12.9–20.3)
F 6,493 1,538 23.7 (22.7–24.7) 20.6 (16.7–25.3) Referent 20.3 (16.4–25.0)
Transgender
 41
 5
 12.2 (4.1–26.2)
 2.8 (0.2–27.6)
 0.093
 2.4 (0.0–27.3)
Age, y
10–19 1,473 351 23.8 (21.7–26.1) 18.9 (14.7–24.0) Referent 18.6 (14.4–23.7)
20–29 2,105 478 22.7 (20.9–24.6) 21.1 (16.8–26.2) 0.211 20.8 (16.5–25.9)
30–39 2,353 535 22.7 (21.1–24.5) 18.5 (14.6–23.1) 0.802 18.2 (14.3–22.8)
40–49 2,353 551 23.4 (21.7–25.2) 19.6 (15.5–24.5) 0.671 19.3 (15.2–24.2)
50–59 1,927 408 21.2 (19.4–23.1) 20.4 (16.1–25.5) 0.419 20.1 (15.8–25.2)
>60
 2,108
 335
 15.9 (14.4–17.5)
 13.4 (10.3–17.4)
 0.001
 13.1 (9.9–17.1)
History of respiratory symptoms
Yes 175 114 65.1 (57.6–72.7) 59.8 (47.5–71.0) <0.001 59.6 (47.3–70.9)
No
 12,073
 2529
 20.9 (20.2–21.7)
 18.3 (14.7–22.5)
 Referent
 18.0 (14.4–22.2)
Contact with COVID-19 case
Yes 173 94 54.3 (46.6–61.9) 45.3 (34.6–56.6) <0.001 45.1 (34.3–56.4)
No 11,938 2,498 20.9 (20.2–21.7) 18.3 (14.8–22.5) Referent 18.0 (14.5–22.2)
Don’t know
 137
 51
 37.2 (29.1–45.9)
 22.1 (14.0–33.1)
 0.363
 21.8 (13.7–32.8)
Ever tested for COVID-19
Yes 496 198 39.9 (35.6–44.3) 34.2 (26.9–42.5) <0.001 33.9 (26.6–42.3)
No
 11,752
 2,445
 20.8 (20.0–21.6)
 18.0 (14.6–22.1)
 Referent
 17.7 (14.3–21.8)
COVID- 19 test result, n = 496
Positive 119 107 89.9 (83.0–94.7) NA NA NA
Negative 342 83 24.3 (19.8–29.2) NA NA NA
Don’t Know
 35
 8
 22.9 (10.4–40.1)
 NA
 NA
 NA
*COVID-19, coronavirus disease; NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

Page created: December 03, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external